Company
Brenig
LRRK2 Inhibitor for Parkinson’s Disease - Brenig Therapeutics
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Brenig Therapeutics develops innovative small-molecule therapies for neurodegenerative diseases, including LRRK2 inhibitors targeting Parkinson’s disease.
Loading relationship preview